期刊文献+
共找到5篇文章
< 1 >
每页显示 20 50 100
鸡肝脏胆汁酸结合蛋白基因启动子活性分析 被引量:1
1
作者 王启贵 高广亮 +2 位作者 马广伟 张心扬 李辉 《东北农业大学学报》 CAS CSCD 北大核心 2014年第4期88-93,共6页
研究对鸡肝脏胆汁酸结合蛋白基因(L-BABP)启动子活性进行研究。利用在线分析软件分析L-BABP基因启动子区,发现CCAAT box(-306)、TATA box(-995)、GATA-1(-1844)和SRE(-1866)等调控元件,没有发现CpG岛。扩增鸡L-BABP基因5'侧翼区约2... 研究对鸡肝脏胆汁酸结合蛋白基因(L-BABP)启动子活性进行研究。利用在线分析软件分析L-BABP基因启动子区,发现CCAAT box(-306)、TATA box(-995)、GATA-1(-1844)和SRE(-1866)等调控元件,没有发现CpG岛。扩增鸡L-BABP基因5'侧翼区约2 kb的DNA片段,构建鸡L-BABP基因报告基因系列缺失载体。报告基因结果表明,鸡L-BABP基因启动子-1 096/-66区域具有最强的启动子活性,-545/-62区域启动子活性最弱;C/EBPα可以显著抑制鸡L-BABP基因的表达,可为深入研究鸡L-BABP的表达调控机制奠定基础。 展开更多
关键词 肝脏胆汁酸结合蛋白 启动子 活性分析
下载PDF
梓醇对糖尿病小鼠肝肾并发症与肝脏胆汁酸作用的研究 被引量:1
2
作者 曾卿 陈小芳 +1 位作者 刘畅 李先恩 《世界中医药》 CAS 2022年第21期3006-3013,共8页
目的:考察梓醇对2型糖尿病小鼠糖代谢及其胆汁酸水平的影响。方法:取高糖高脂饲料喂养的实验用糖尿病纯合子(db/db)小鼠作为2型糖尿病模型,随机分为模型组、阳性药组和梓醇低剂量组、梓醇中剂量组、梓醇高剂量组,以糖尿病导入m基因杂合... 目的:考察梓醇对2型糖尿病小鼠糖代谢及其胆汁酸水平的影响。方法:取高糖高脂饲料喂养的实验用糖尿病纯合子(db/db)小鼠作为2型糖尿病模型,随机分为模型组、阳性药组和梓醇低剂量组、梓醇中剂量组、梓醇高剂量组,以糖尿病导入m基因杂合子(db/m)小鼠作为正常组,给药8周后,检测小鼠体质量、血糖、肝功能及视网膜病理变化,并利用超高效液相色谱法-三重四极杆-线性离子阱质谱(UPLC-QTRAP-MS/MS)分析肝脏胆汁酸水平。结果:与模型组比较,梓醇显著控制db/db小鼠体质量并降低其血糖、糖耐量、血清谷丙转氨酶(GPT)、谷草转氨酶(GOT)、总胆红素(T-Bil)、血清白蛋白、直接胆红素(D-Bil)和间接胆红素(I-Bil)水平,且有效降低脏器系数(P<0.05)及改善肝脏和视网膜损伤;同时发现,梓醇与二甲双胍显著降低糖尿病小鼠肝脏中的熊去氧胆酸(UDCA)水平(P<0.05),且提高了小鼠肝脏中的石胆酸(LCA)、脱氧胆酸(DCA)与鹅去氧胆酸(CDCA)水平(P<0.05)及叶酸(FA)、维生素B_(12)的水平。结论:梓醇能通过调节肝脏胆汁酸水平来调节2型糖尿病小鼠的糖代谢,改善肝脏和视网膜损伤,并降低周围神经病变的风险。 展开更多
关键词 梓醇 2型糖尿病 db/db小鼠 肝肾并发症 视网膜损伤 周围神经病变 超高效液相色谱法-三重四极杆-线性离子阱质谱 肝脏胆汁酸
下载PDF
鸡肝脏脂肪酸结合蛋白的研究进展 被引量:2
3
作者 王启贵 张庆秋 王丽辉 《黑龙江畜牧兽医》 CAS 北大核心 2011年第12期33-35,共3页
脂肪酸结合蛋白(FABPs)属于脂结合蛋白超家族成员,是一类分子质量较小而对脂肪酸有高亲和力的蛋白质,广泛存在于脊椎动物和非脊椎动物的细胞质中,对脂类代谢具有重要的调控作用。鸡肝脏在脂肪酸代谢中发挥着重要的作用,大量的脂肪酸在... 脂肪酸结合蛋白(FABPs)属于脂结合蛋白超家族成员,是一类分子质量较小而对脂肪酸有高亲和力的蛋白质,广泛存在于脊椎动物和非脊椎动物的细胞质中,对脂类代谢具有重要的调控作用。鸡肝脏在脂肪酸代谢中发挥着重要的作用,大量的脂肪酸在肝脏中合成,酯化后随血液循环到达全身各处。鸡的肝脏组织中存在2种脂肪酸结合蛋白,即肝脏脂肪酸结合蛋白(L-FABP)和肝脏胆汁酸结合蛋白(L-BABP),文章对这2个基因的结构、染色体定位、空间构象及功能进行了综述。 展开更多
关键词 肝脏 肝脏脂肪结合蛋白 肝脏胆汁酸结合蛋白
下载PDF
Measurement of hepatic functional mass by means of ^(13)C-methacetin and ^(13)C-phenylalanine breath tests in chronic liver disease: Comparison with Child-Pugh score and serum bile acid levels 被引量:35
4
作者 D.Festi S.Capodicasa +9 位作者 L.Sandri L.Colaiocco-Ferrante T.Staniscia E.Vitacolonna A.Vestito R.Simoni G.Mazzella P.Portincasa E.Roda A.Colecchia 《World Journal of Gastroenterology》 SCIE CAS CSCD 2005年第1期142-148,共7页
AIM: To evaluate and compare the clinical usefulness of 13C-phenylalanine and 13C-methacetin breath tests in quantitating functional hepatic mass in patients with chronic liver disease and to further compare these res... AIM: To evaluate and compare the clinical usefulness of 13C-phenylalanine and 13C-methacetin breath tests in quantitating functional hepatic mass in patients with chronic liver disease and to further compare these results with those of conventional tests, Child-Pugh score and serum bile acid levels.METHODS: One hundred and forty patients (50 HCV-related chronic hepatitis, 90 liver cirrhosis patients) and 40 matched healthy controls were studied. Both breath test and routine liver test, serum levels of cholic and chenodeoxycholic acid conjugates were evaluated.RESULTS: Methacetin breath test, expressed as 60 min cumulative percent of oxidation, discriminated the hepatic functional capacity not only between controls and liver disease patients, but also between different categories of chronic liver disease patients. Methacetin breath test was correlated with liver function tests and serum bile acids.Furthermore, methacetin breath test, as well as serum bile acids, were highly predictive of Child-Pugh scores. The diagnostic power of phenylalanine breath test was always less than that of methacetin breath test.CONCLUSION: Methacetin breath test represents a safe and accurate diagnostic tool in the evaluation of hepatic functional mass in chronic liver disease patients. 展开更多
关键词 Chronic hepatitis c Liver cirrhosis Breath Tests Hepatic functional mass
下载PDF
Bile-acid-activated farnesoid X receptor regulates hydrogen sulfide production and hepatic microcirculation 被引量:8
5
作者 Barbara Renga Andrea Mencarelli +2 位作者 Marco Migliorati Eleonora Distrutti Stefano Fiorucci 《World Journal of Gastroenterology》 SCIE CAS CSCD 2009年第17期2097-2108,共12页
AIM: To investigate whether the farnesoid X receptor (FXR) regulates expression of liver cystathionase (CSE), a gene involved in hydrogen sulfi de (H2S) generation. METHODS: The regulation of CSE expression in respons... AIM: To investigate whether the farnesoid X receptor (FXR) regulates expression of liver cystathionase (CSE), a gene involved in hydrogen sulfi de (H2S) generation. METHODS: The regulation of CSE expression in response to FXR ligands was evaluated in HepG2 cells and in wild-type and FXR null mice treated with 6-ethyl chenodeoxycholic acid (6E-CDCA), a synthetic FXR ligand. The analysis demonstrated an FXR responsive element in the 5'-flanking region of the human CSE gene. The function of this site was investigated by luciferase reporter assays, chromatin immunoprecipitation and electrophoretic mobility shift assays. Livers obtained from rats treated with carbon tetrachloride alone, or in combination with 6-ethyl chenodeoxycholic acid, were studied for hydrogen sulphide generation and portal pressure measurement. RESULTS: Liver expression of CSE is regulated by bile acids by means of an FXR-mediated mechanism. Western blotting, qualitative and quantitative polymerase chain reaction, as well as immunohistochemical analysis, showed that expression of CSE in HepG2 cells and in mice is induced by treatment with an FXR ligand. Administration of 6E-CDCA to carbon tetrachloride treated rats protected against the down-regulation of CSE expression, increased H2S generation, reduced portal pressure and attenuated the endothelial dysfunction of isolated and perfused cirrhotic rat livers. CONCLUSION: These results demonstrate that CSE is an FXR-regulated gene and provide a new molecular explanation for the pathophysiology of portal hypertension. 展开更多
关键词 Nuclear receptor Farnesoid X receptor Cystathionase Hydrogen sulfide Portal hypertension
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部